Deep Vein Thrombosis (DVT) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Deep Vein Thrombosis (DVT) – Drugs In Development, 2024 report and make more profitable business decisions.
Deep vein thrombosis (DVT) is a blood clot that forms in a vein deep inside a part of the body. It mainly affects the large veins in the lower leg and thigh. Symptoms include changes in skin color (redness), leg pain, leg swelling (edema), and skin that feels warm to the touch. The predisposing factors include age, smoking, inheriting a blood-clotting disorder, injury or surgery, cancer, inflammatory bowel disease, and heart failure. Treatment includes thrombolytics and anticoagulants.
The Deep Vein Thrombosis (DVT) drugs in development market research report provide comprehensive information on the therapeutics under development for Deep Vein Thrombosis (DVT), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Deep Vein Thrombosis (DVT) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Deep Vein Thrombosis (DVT) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 17 molecules, with 17 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Deep Vein Thrombosis (DVT) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Deep Vein Thrombosis (DVT) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Deep Vein Thrombosis (DVT) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Anthos Therapeutics IncBayer AG
Bio-Synectics Inc
CarboMimetics
China Resources Emde Biological Pharmaceutical Co Ltd
Glycan Therapeutics Inc
Guangzhou Dazhou Biomedical Technology Co Ltd
Kolmar Korea Co Ltd
Laboratorios Farmaceuticos Rovi SA
Marizyme Inc
Protheragen Inc
Taho Pharmaceuticals Ltd
Tianjin Pharmaceuticals Group Co Ltd
Zerion Pharma AS
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Deep Vein Thrombosis (DVT) reports